Black Rose Industries: consolidated PAT +137% YoY on margin rebound, revenue up 4%
PAT +136.87% YoY · revenue +4.41% · margins expanding
₹87.68 Cr
+4.41% YoY
₹10.49 Cr
+136.87% YoY
11.5%
+6.3pp YoY
₹2.06
Black Rose Industries' consolidated PAT for Q2 FY27 (quarter ended 30 September 2026) came in at ₹10.49 Cr, up 137% year-on-year from ₹4.43 Cr in Q2 FY26, while revenue from operations grew a much more modest 4.4% YoY to ₹87.68 Cr (₹83.98 Cr a year ago). Sequentially the print was flat — PAT up just 0.9% QoQ and revenue down 1.6% QoQ from Q1 FY27's ₹10.39 Cr PAT and ₹89.08 Cr revenue — so the YoY jump, not the QoQ number, is the real story this quarter; with revenue barely moving QoQ, the sequential comparison itself carries little signal beyond confirming the business has held its new, higher margin level.
Q2 FY-2027 vs prior quarters
The entire YoY profit surge is a margin story rather than a volume story. Total expenses fell to 87.8% of revenue from 93.2% a year ago, lifting operating margin (OPM) to 13.8% from 8.6% YoY and net margin (NPM) to 11.5% from 5.3% YoY. Sequentially, margins eased slightly — OPM from 16.1% to 13.8% and NPM roughly flat at 11.5% vs 11.53% — as the expense ratio ticked up from 85.3% to 87.8% of revenue QoQ. EPS tracked the profit line: ₹2.06 this quarter versus ₹0.87 a year ago and ₹2.04 last quarter.
The stock went into the print at ₹97.8, down 12.5% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters.
What the summary numbers don't show
No exceptional items in either period — standalone and consolidated PAT differ by only ₹0.002 Cr
Management highlighted strong Q4 performance driven by both distribution and manufacturing segments, with revenue up 38% and EBITDA up 90%. The company expects continued revenue growth in the upcoming year, driven by new product additions and expanding end-user customer bases in both distribution and manufacturing. Whi
— This quarter: met
No brokerage estimates for Black Rose could be found in a web search (public trackers show zero analysts covering the stock), so there is no street print to grade against; vsStreet is unknown. Against the company's own May 2026 concall guidance — subdued near-term distribution demand offset by higher pricing and a strong merchant-export pipeline, plus a positive manufacturing/acrylamide export outlook — this quarter's combination of muted topline growth with sharp margin recovery is broadly on-script, so the result reads as a guidance-met quarter rather than a beat or miss. No separate management press release accompanied this filing to cross-check against. At the same board meeting (6 November 2026) the company also approved Srishti Gour's appointment as Company Secretary and Compliance Officer; the VP Innovation's resignation in October and the routine SEBI KYC/insider-trading-window items from September are unrelated to the financial print.
W1
Whether the acrylamide export demand pickup flagged in the May 2026 concall lifts revenue growth beyond the current ~4% YoY pace
W2
Status of the Specialty Amines project decision, which management said could come 'this year' (CY2026) as of the May 2026 call
W3
Whether operating margin holds near the 13-14% level reached this quarter or reverts toward the prior ~8-9% YoY base as the B.R. Chemicals (Japan) wind-up concludes
Standalone and consolidated are nearly identical since the sole subsidiary (B.R. Chemicals Co., Japan) is being wound up and is reported as discontinued operations with a negligible ₹0.0021 Cr quarterly loss; no exceptional items in either comparative period.